One of the world’s most popular metal products used in aerospace and defence industries will soon be produced in the United Kingdom with metal additives specialist Titomic (ASX: TTT) partnering with UK-based Neos to manufacture and sell the products.
The joint venture is an extension of existing business between Titomic and Neos which will draw upon Titomic’s Kinetic Fusion Technology and Neos’ tooling expertise to manufacture Invar 36 Faceplates and multi-metal product solutions.
By joining forces on this project, the companies will be able to optimise production efficiency which in turn will provide support for the next-generation of Defence aircraft.
“We are excited about working with Neos to manufacture high-performance solutions in the United Kingdom using our Kinetic Fusion Technology, providing reduced lead times to the Aerospace sectors by combining Neos’ well established engineering expertise and Titomic’s high-speed additive manufacturing technology,” said Titomic Interim CEO, Norbert Schulze.
Enhancing the rapid delivery of Invar and Nickel Shell Tooling and related products to the aerospace and defence sectors, the joint venture partners are confident they can together accelerate advanced carbon fibre composite technologies. In doing so, this would facilitate production of lightweight fuel-efficient aircraft and support the UK’s nascent Space Industry.
“Titomic is a leading company with proven reliability in metal additive manufacturing so, having them as our joint venture partner, will be extremely beneficial in producing large scale additively manufactured solutions for the Aerospace Industry, as well as a beneficial technology to support the changing Defence landscape,” said Neos CEO, Carl Roberts.
The JV is part of Titomic’s corporate strategy to leverage their additive manufacturing solutions, targeting international partners. It follows a similar deal signed last week with Repkon to manufacture weapons system barrels in Australia.
Adelaide-based metal printing group books record $12.5 million revenue and a record $78 million sales…
Harris Technology has found a higher-margin growth engine in an unlikely place: the market for…
Imagion Biosystems (ASX: IBX) is moving its MagSense® HER2 Imaging Agent Phase 1b/2 clinical trial…
Acrux (ASX:ACR) is set to bring its transdermal Estradiol spray Lenzetto® to the Australian market…
The race to secure Western-aligned critical minerals supply chains is accelerating as governments and industry…
Green360 Technologies (ASX:GT3) has taken a major step forward in the commercialisation of its low-carbon…